Inmagene Biopharmaceuticals Virtual KOL Event to Discuss the Potential Role of Anti-OX40/OX40L Monoclonal Antibodies (mAbs) in the Treatment of Alopecia Areata (AA)
| DATE: | May 28, 2025 |
|---|---|
| TIME: | 11:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Join Inmagene Biopharmaceuticals for a virtual key opinion leader (KOL) event featuring Emma Guttman, MD, PhD (Icahn School of Medicine at Mount Sinai), who will discuss the current treatment landscape for patients with alopecia areata (AA) and the potential role of biologics targeting the OX40/OX40L signaling in addressing treatment gaps in AA.
The event will review emerging data from the Phase 2a AA trial of Inmagene’s IMG-007, the only clinical-stage non-depleting anti-OX40 receptor monoclonal antibody.
A live question and answer session will follow the formal presentations.